{"name":"Verastem, Inc.","slug":"verastem-inc","ticker":"","exchange":"","domain":"verastem.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":30914000,"revenueGrowth":209.1,"grossMargin":0,"rdSpend":114599000,"netIncome":-209471000,"cash":204990000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2025"},"revenueBreakdown":[],"timeline":[{"date":"2025-01-01","label":"Avmapki Fakzynja Co-Pack first approved","drug":"Avmapki Fakzynja Co-Pack","drugSlug":"avutometinib","type":"approval","sentiment":"positive"},{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-12-01","label":"Avmapki Fakzynja Co-Pack PHASE2 readout","drug":"Avmapki Fakzynja Co-Pack","drugSlug":"avutometinib","type":"phase3_readout","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"Avmapki Fakzynja Co-Pack","genericName":"AVUTOMETINIB","slug":"avutometinib","indication":"KRAS-mutated recurrent low-grade serous ovarian cancer (LGSOC)","status":"marketed"},{"name":"Gemcitabine + Nab-paclitaxel","genericName":"Gemcitabine + Nab-paclitaxel","slug":"gemcitabine-nab-paclitaxel","indication":"Metastatic pancreatic cancer","status":"phase_3"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"immunology","drugs":[{"name":"PF-04554878","genericName":"PF-04554878","slug":"pf-04554878","indication":"Other","status":"phase_1"},{"name":"VS-6063","genericName":"VS-6063","slug":"vs-6063","indication":"Other","status":"phase_2"}]}],"pipeline":[{"name":"Avmapki Fakzynja Co-Pack","genericName":"AVUTOMETINIB","slug":"avutometinib","phase":"marketed","mechanism":"Avmapki Fakzynja Co-Pack works by blocking a protein that helps cancer cells grow.","indications":["KRAS-mutated recurrent low-grade serous ovarian cancer (LGSOC)","KRAS-mutated recurrent low-grade serous ovarian cancer (LGSOC)"],"catalyst":""},{"name":"Gemcitabine + Nab-paclitaxel","genericName":"Gemcitabine + Nab-paclitaxel","slug":"gemcitabine-nab-paclitaxel","phase":"phase_3","mechanism":"Gemcitabine and nab-paclitaxel work together as a chemotherapy combination to disrupt cancer cell division and microtubule stability.","indications":["Metastatic pancreatic cancer","Non-small cell lung cancer","Breast cancer"],"catalyst":""},{"name":"PF-04554878","genericName":"PF-04554878","slug":"pf-04554878","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"VS-6063","genericName":"VS-6063","slug":"vs-6063","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"date":"2026-03-04","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"date":"2026-03-04","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixwFBVV95cUxPazhHcEtJa1hEQjNGZGRZcG5MaXZQUDZFMTIyTkhCd3NOS3Vuei0tdEZJS0V5OVIxY2Z4bld6TE85MEwwaGNhNEV5bWR4d2JMaXdleDJfeXFJdUR0aF90YjVRRkVLMy1CMnVsblQyZFhJRnlSWFZxUEcya0pOc2xVcEpfNlB1UWtSR0RsZzhSc1hpV0Z1WC02cVMtdlhCazFCLUU2MVZNT1NISTlCX0VhUTA4RXZjZDdNQUdTUm5WVW5fWExxdDBN?oc=5","date":"2026-02-27","type":"pipeline","source":"AD HOC NEWS","summary":"Verastem (VSTM): Can This Beaten-Down Biotech Still Surprise Wall Street? - AD HOC NEWS","headline":"Verastem (VSTM): Can This Beaten-Down Biotech Still Surprise Wall Street?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilgJBVV95cUxNNHppcTlmYldTazVFOTVtd1FjVGRwamUyNG14SFJ5MjhKVG9iX2tSMEZvNnNKbUxoS3VRd1RqREp0RTNoZVM2Q240NkRjWUFRODlKbVNVWXlwRUktUkNkRFluY0o3c1BsS01HWjZGR2pJRVlNbnBldzMwUzh1WEpuUm5vdERKejBQb0NNSWVfMjJacldNU2VhNVBVa0dZTHByWTM1MXdxLXJHdFZ1SncyQmV2OUtWNllTMldLT1lRN0drUjQwZFZrb1NpbE44eHNrcS1QbGdtWmpEMU5qOVc0OEdTcDNPZHctOTVVdm9HNV9kVnE5WFdISGt3dnc3ZE1FdzAzekV0UXgya2lEY1E0VElWTUczdw?oc=5","date":"2026-02-05","type":"pipeline","source":"The Globe and Mail","summary":"Analysts Offer Insights on Healthcare Companies: Voyager Therapeutics (VYGR), InflaRx (IFRX) and Verastem (VSTM) - The Globe and Mail","headline":"Analysts Offer Insights on Healthcare Companies: Voyager Therapeutics (VYGR), InflaRx (IFRX) and Verastem (VSTM)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuAFBVV95cUxQSl9OVEVSc204TzB5MmpoU29IV1pJOUNVNXptdlFHWVQzQS11QWJVdlNjNThtMEtLc3Q0TlllSlNCbzNLTlUzX2s4dnN1eHlCdHo3SXZBYnE0OGwwT1QtWEVsTEJNUjJjQ1dUTXR2RTh1bVhTT2wwN3o5VWtnQ0swRkh3Nnp1SWZaVmpEUU5OY1RUUi1Xbnc3Yk5IcDRqTzJYTzZxQ296QTBid0FtSGhjTEhaalFVeWxy?oc=5","date":"2026-02-04","type":"pipeline","source":"Stock Titan","summary":"Cancer drugmaker turns to KRAS pill after $30.9M launch year - Stock Titan","headline":"Cancer drugmaker turns to KRAS pill after $30.9M launch year","sentiment":"neutral"},{"date":"2026-02-04","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"date":"2026-01-08","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi2gFBVV95cUxNTFQ3OXg0V283RG1ybjM3YnhySkdGUnVETmF3YlNvZjkxeUJLNjB4bEN6V09BTzlzZ2pQTHB4X2tzY1VXdUNGU3VpMUdHaVZVdzQ1U2lHOGpscjl2Q3JXdThONGlEMl9YR1BobzFKQ1VacV9HV1ZLbE1wZDBJVWtibWZMS0hBZDNqcnNYOEl1QTY5Qk5xSFlQN0tUOE9wckdDcGEyVVRvREwwcnRZd2piaEpwVG5LU0xRWGxPVVVlbWVqbjVWR0dTY0RzYkJBSWl5TXIyMWQwTGhHd9IB3wFBVV95cUxQYS1CSGFHQWU2aTFhMkw3X1JXaUFRelo0VXg4MHBHUHlRWkRuNXBFS3hQOXV6bVk4cHBGWkZyb2FxZVpZdXhfYk1SZWFOS0p1VWpMdzROaW85SnlGcENXazZEVWlqNXJqd2VKRVdTbmJSTDQxVExhcldoUE5wa1lodWhXRXdubzFtOVdBVVp2c05nakstUFBTYTk5WWhDSm1WVE42eVl5NlZBLXZIZjh2SDdDSS1TUTBpR0paNkdySlROdmFBbDIwdWJRMWFQUUtXQVlXSGxsbGNCWkZ1aFJn?oc=5","date":"2025-12-26","type":"pipeline","source":"simplywall.st","summary":"Verastem, Inc.'s (NASDAQ:VSTM) Share Price Is Still Matching Investor Opinion Despite 26% Slump - simplywall.st","headline":"Verastem, Inc.'s (NASDAQ:VSTM) Share Price Is Still Matching Investor Opinion Despite 26% Slump","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijgFBVV95cUxOUDVoQW1ZT2cyY3BjczZ1dXN6REZSemlQbkU3aXdVRWZROTBCZ1diTnkwQUJTaWhUdmZnM1plWEdkNFFnY3NXS3RpM2tkLVd5bjM2TFF3eTJWdV9GOEdkaGNxRGI4dUhvMDA1SERwLVl1QjJ1Ylc3MF85Y1g1cHpYMDM1eVVhcVZMVENuRWJn?oc=5","date":"2025-07-16","type":"pipeline","source":"Seeking Alpha","summary":"Verastem: The Market Is Ignoring The Progress (NASDAQ:VSTM) - Seeking Alpha","headline":"Verastem: The Market Is Ignoring The Progress (NASDAQ:VSTM)","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-06-23","type":"earnings","source":"simplywall.st","summary":"Verastem, Inc.'s (NASDAQ:VSTM) institutional investors lost 13% over the past week but have profited from longer-term gains - simplywall.st","headline":"Verastem, Inc.'s (NASDAQ:VSTM) institutional investors lost 13% over the past week but have profited from longer-term ga","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuwJBVV95cUxPSlFhcVdwaFlONm5LenM3akJpY2hmc04zT3hMeWFVMm50ZTBMTWNZNlFWRFBUOUdJZ010blhQNkpKR1gzd2NwN0lDOXFRQlFQVmZZSW82aDRiYU94a3VaZDkxWWsxTWJGUEJlNnJWa1pGV2FEZkFLX3QyVWJJSDQ2ajgxZnVQY25wZnloZ3RBOVR4RGhSZ1REYjhHWGhzeTlmVjFmbEQ5b1ZSTktKQzltVDM0bHdBNm1DSEM2S1VSbEl0a0QybjUzZE5laFF2YTFqSkZNYlVrdXBKQm9lVjlZTTZiSDMwa3YzMUgwaHAxeV82LVNKZTFoZUI5ZG1NbThqUlE5bEFBUWJ6Rm5XcVV5Q2VWNl9NREdCN2lycUhOU2otUEh6NDBmSERtS3VPaENoMnI3M0tKRmxmTjg?oc=5","date":"2025-05-13","type":"trial","source":"GlobeNewswire","summary":"Metastatic Colorectal Cancer Clinical Trial Pipeline - GlobeNewswire","headline":"Metastatic Colorectal Cancer Clinical Trial Pipeline","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMirgFBVV95cUxPSG1FWGQ5TXczX29yUjVMcWZIeFktaF9Mc0U5NGFXNGVDOTRLbWh5X2VNX0lPMnpPSF9kd1ZPNWZJcHBsR0x1Sm1iR2E5THdjMTJLNDBkeWlYcEJjVEw4OU53WVV3X3FxdVg5eTltSWlkWHBqR1VCSG9KUC04cnVxWmM3NU9FbURsWGI5dEloaW8tUWs3X3JPWlFBMUgxcGl5eE1kTTVxUzJwNExiQnc?oc=5","date":"2025-05-09","type":"regulatory","source":"Fierce Pharma","summary":"Verastem scores FDA nod for first-of-its-kind oral combination to treat rare form of ovarian cancer - Fierce Pharma","headline":"Verastem scores FDA nod for first-of-its-kind oral combination to treat rare form of ovarian cancer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirAFBVV95cUxPT201a1VJcDFWV19iekZQTnpQMDdVRzU2WWF4Z3RMcEMyWXFiT0RXcTFuUlJqb2FhRDFrZWJrbFdiY3lmakdpekJ2Tkx2c3JlRkg2N096S2VUblZuQndwM25tSmM1ODhUSjRWWEFfQ2RoTjFhbzc3NkVsbFZMYkJ0X09halI3aVVUbVpwWjdxUThseGlrYWs5M1Y4d2Y0RUFCX1BaSng1MTBadGZM?oc=5","date":"2025-05-09","type":"regulatory","source":"The Institute of Cancer Research","summary":"ICR welcomes approval for new ovarian cancer drug combination - The Institute of Cancer Research","headline":"ICR welcomes approval for new ovarian cancer drug combination","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMisgFBVV95cUxQRk0yd3pOclRickg0NkhpYl90Q3c0SThxUFlNSS1TcjBhS011NkN3UXVRX0M3Z3RTa0NHd2VjVzl6d19Eck1RdlhjQkk0RHIxTmFVOHhFV1k5YTNZcE1zbldrSkhNaUoxQVoyb0Ywck01SjJ1VUhZak9hN2MzakR4Y2VNQUNoVEVZMTc1NUl6OUxCRS1qS1QxRFRvc1FoU1BlTXdDaWpmX2ltc3phdlNpUF93?oc=5","date":"2025-05-08","type":"regulatory","source":"Reuters","summary":"US FDA approves Verastem's ovarian cancer therapy - Reuters","headline":"US FDA approves Verastem's ovarian cancer therapy","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiwAFBVV95cUxPcHZIb040TnlHNmp0Y2ZDNVl4UU94bUZORE5KSGItREhsajdNdUUxUnZveTZKSUlBaHlzVVZPazI3c2k5SU1EWFFGNHh3RHF4aU5UTUlNb1Q4NUxGQ2pVUU5KQmlPR2tYQnp2T2hTZDBOU0VXeEp5WHVubUE0aW4wYXh0YzFwQlAtZWNOX09RUjhoMWh0bGc3NXFrX0gxaUJDRURicUh5bThUbXlPNFdaSUM5UTlXblU5Q2tzR2FxRno?oc=5","date":"2025-05-08","type":"regulatory","source":"MedCity News","summary":"Accelerated FDA Approval Makes Verastem Drug the First Therapy for Rare Type of Ovarian Cancer - MedCity News","headline":"Accelerated FDA Approval Makes Verastem Drug the First Therapy for Rare Type of Ovarian Cancer","sentiment":"positive"}],"patents":[],"drugCount":4,"phaseCounts":{"marketed":1,"phase_3":1,"phase_1":1,"phase_2":1},"enrichmentLevel":3,"visitCount":6,"keyCompetitors":[],"therapeuticFocus":[],"financials":{"source":"sec_edgar+yahoo","revenue":30914000,"revenuePeriod":"2025-12-31","revenueHistory":[{"value":30914000,"period":"2025-12-31"},{"value":10000000,"period":"2024-12-31"},{"value":2596000,"period":"2022-12-31"},{"value":2053000,"period":"2021-12-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":114599000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-209471000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":204990000,"cashHistory":[],"totalAssets":246442000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}